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ABSTRACT
RNA interference (RNAi) is an ancient intra-cellular
mechanism that regulates gene expression and cell
function. Large-scale gene silencing using RNAi high-
throughput screening (HTS) has opened an exciting
frontier to systematically study gene function in mam-
malian cells. This approach enables researchers to
identify gene function in a given biological context and
will provide considerable novel insight. Here, we review
RNAi HTS strategies and applications using case stud-
ies in cancer biology and virology.
KEYWORDS RNA interference (RNAi), short interfering
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INTRODUCTION
Thesystematic genenetworks remain challenging, aftermany
genomes from different species have been sequenced within
the last two decades (Adams et al., 2000; Lander et al., 2001;
Waterston et al., 2002; Yu et al., 2002). Although the functions
of an increasing number of gene products have been
revealed, a major challenge in the post-genomic era remains
to clarify the precise roles of these genes in speciﬁc biological
processes and ultimately to develop new strategies to ﬁght
diseases. RNA interference (RNAi) technology (Fire et al.,
1998) is a powerful tool to study gene function by silencing
transcription. Signiﬁcant progress has beenmade using RNAi
technology in the investigation of the molecular basis of can-
cer development. Such studies have identiﬁed several novel
oncogenes, such as sequence similarity 83, member B
(FAM83B) in breast cancer (Cipriano et al., 2012), LIM-
homeodomain-containing transcription factor 1B (Lmx1b),
p21-activated kinase 4, inhibitor of apoptosis-stimulating
protein of p53 (iASPP), and stem cell transcription factor Na-
nog in ovarian cancer (Siu et al., 2010; Jiang et al., 2011; He
et al., 2013; Siu et al., 2013), and abnormal spindle homo-
logue, microcephaly associated (ASPM) in glioblastoma
(Horvath et al., 2006). Signiﬁcant progress has also been
made in the ﬁeld of host immune responses against virus
infections using RNAi technology. Indeed, many novel genes
involved in virus entry and replication in the host have been
uncovered (Brass et al., 2008; Brass et al., 2009).
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With such technological advances, it is now feasible to
interrogate phenotypes associated with the loss-of-function
of many genes in mammalian cell culture systems. Further-
more, it becomes possible to construct genome-wide RNAi
libraries that systematically target every individual gene in a
given genome to perform high-throughput screening (HTS)
of speciﬁc phenotypes of interests (Silva et al., 2008). The
combination of RNAi and HTS in cell culture systems, known
as cell-based RNAi HTS, is a new and exciting frontier in
basic and applied biology. Inevitably, such a powerful
methodology has led to signiﬁcant progress in many areas of
cancer biology, i.e., the crosstalk of biological signaling and
the identiﬁcation and validation of cancer therapeutic targets
(Moffat and Sabatini, 2006; Iorns et al., 2007).
In this review, we provide an overview of RNAi and RNAi
HTS in cell systems. Different technical strategies are
described using case studies as examples. Finally, discus-
sions are made in the context of the existing problems with
these screens.
RNAi
RNAi is an evolutionarily conserved mechanism that regulates
gene expression in eukaryotic cells. In this process, double-
stranded RNAs (dsRNAs) can suppress the expression of tar-
get genes in a homology-dependent manner (Hannon, 2002;
Almeida and Allshire, 2005). The effectors of RNAi are short
interfering RNAs (siRNAs) produced from long dsRNA sub-
strates by an RNAse III enzyme called Dicer. These Dicer
products are 20- to 25-bp-long dsRNAs with a characteristic
2-nt overhang at the 3′-end (Fire et al., 1998; Bernstein et al.,
2001). The siRNA duplexes are incorporated into the RNA-
induced silencing complex (RISC) containing a core Argonaute
(AGO)protein thatdestroysa “passenger strand”andkeeps the
“guiding strand” that hybridizes to the target mRNA by com-
plementary homology. Such a homology-based association
allows theAGO todegrade themRNA transcript, or to inhibit the
mRNA translation, resulting in post-transcriptional gene
silencing (Martinez et al., 2002; Hock and Meister, 2008).
In mammalian cells, long dsRNAs induce interferon
responses, which are the ﬁrst line of defense against viral
infections, and subsequently lead to a global shutdown of
protein synthesis (Reynolds et al., 2006). However, vectors
expressing short hairpin RNAs (shRNAs) and/or synthetic
siRNAs designed to mimic endogenous 21-nt siRNAs can be
manually introduced into mammalian cells to avoid the
interferon response, thus mediating gene silencing without
signiﬁcant adverse effects (Elbashir et al., 2001; Kim and
Rossi, 2007). With the availability of completely sequenced
genomes, siRNA or vector-based shRNA libraries can be
constructed with speciﬁc designs to maximize the probability
of potent target gene silencing and to minimize the risk of off-
target effects (Huesken et al., 2005; Turner et al., 2008). To
date, RNAi has been successfully developed to become a
powerful experimental tool (Huang et al., 2013)
RNAi HTS
Traditionally, functional genetic studies have been performed
by so called forward genetics, in which random gene muta-
tions are generated by induction (e.g., radiation, chemical
treatments, and/or insertional mutagenesis), and then
mutants with speciﬁc phenotypes are identiﬁed by breeding
and segregation processes (Gao et al., 2008; Lawson and
Wolfe, 2011). However, such procedures are time-consum-
ing and not easily applicable to mammalian cell systems.
Conversely, reverse genetic strategies focus on the mutants
of a gene of interest by observing the phenotype so as to
determine the gene function (Wang et al., 2011). Traditional
gene knockouts, either in cell systems or living organisms,
are expensive, time-consuming, and unsuitable for genome-
scale screens. Using RNAi technology, a gene that is
required for a certain function can be silenced by the intro-
duction of siRNAs, and the corresponding phenotype can be
determined by appropriate assays. This fascinating link
between phenotype and RNAi-mediated gene silencing has
promoted rapidly growing applications of RNAi in functional
genomics, signal transduction, and drug target discovery. As
such, RNAi represents a major technological advance for
performing large-scale screenings in cell culture systems
(Echeverri and Perrimon, 2006). HTS is a procedure that
supports large-scale experiments, allowing a researcher to
quickly conduct thousands or millions of chemical screens or
genetic tests simultaneously (Krausz, 2007).
RNAi HTS METHODS
In the initial stage of an RNAi HTS experiment, the purpose of
the screening should be clear, such as the identiﬁcation of
regulators for cell proliferation, size, morphology, adhesion,
death, division, or the efﬁcacy of viral infection. These ques-
tions enable researchers to develop corresponding pheno-
typic assays that should be clearly deﬁned and easily scored
with interpretations in relevant biological contexts (Boutros
and Ahringer, 2008). Then, one can choose the appropriate
type of RNAi library to screen (i.e., either genome-wide or for a
subset of gene families of interest) and develop robust and
reproducible assays for identiﬁcation, validation, and charac-
terization of candidate genes (Fig. 1A). Technical details that
should be considered include: i) delivery methodology of the
RNAi, ii) raw data collection, iii) appropriate positive and
negative controls that can be used to optimize the discrepancy
between genuine signals and background noise, iv) statistical
methods that can deﬁne the initial hits, v) secondary validation
assays to ﬁlter the primary hits, and vi) function determination
of selected hits (Fig. 1B) (Sharma and Rao, 2009).
Currently, there are two major types of RNAi libraries that
are widely used by researchers: siRNA and vector-based
shRNA libraries. siRNA can be chemically synthesized or
generated from cDNA templates by RNase III via a technique
known as esiRNA, in which gene cDNAwith RNA polymerase
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promoter ampliﬁed by PCR is transcribed in vitro, and then its
products is digested by RNase III to generate siRNAs that is
similar to siRNAs generated in vivo by Dicer. These multiple
silencing triggers result in higher effective gene silencing and
lower off-target effects compared to single and pooled siRNAs
(Yang et al., 2002; Kittler et al., 2004). Synthetic siRNA
libraries are used for most situations for short-term gene
silencing because these siRNA duplexes are not replicated
and are progressively diluted as cells divide. Vector-based
shRNA libraries are deﬁned according to the type of viral
vector used, e.g., retroviral, adenoviral, or lentiviral. Vector-
based shRNA libraries are able to provide long-term and
stable gene silencing because the vectors integrate into
genomic DNA and are thus replicated. In particular, lentiviral-
based shRNA libraries are quite useful in some cells, such as
primary cells, that are difﬁcult to transfect.
There are two distinguishable strategies used in RNAi
screens. One is the array-based screen, and the other is
pooled shRNA libraries coupled to next generation sequenc-
ing. In the array-based screen, both siRNA and shRNA can be
used in this format. There are many factors to affect the gen-
eration of shRNAs, so it is hard to balance the concentration of
every shRNA in HTS. However, the chemically synthesized
siRNAs are easily to handle to titer their concentrations (Liu
et al., 2010). Each gene of interest can be targeted by siRNA
pools in one well, which is composed of three to six individual
non-overlapping siRNAs, or by individual siRNAs in separated
wells. After transfection (48–72 h), cells are divided into
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Figure 1. Flowchart of RNAi high-throughput screening. (A) The design and steps of a high-throughput screen. The choice of
screen libraries such as scale, type, or format can be determined based on biological questions or the phenotypic assays developed.
(B) Data analysis (Gao et al., unpublished data). Raw data can be analyzed according to your choice of statistical methods. Every
experiment is subject to quality control (QC). If QC is passed, the primary hits are selected for a second round of screening. The ﬁnal
hits can be conﬁrmed and further characterized using molecular biology, cell biology, or bioinformatics to determine their biological
meanings.
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different groups that can be treated with different selective
pressures. For example, cells are treated with or without a
drug for another 3–7 days and then examined for the pheno-
type of interest. In the case of using siRNA pools, screening is
normally conducted in duplicate or triplicate in the ﬁrst round,
and then the pools are rescreened using the deconvoluted
individual siRNAs to conﬁrm ﬁnal hits. In the pooled format, off-
target effects of siRNAs are reduced as the concentration of
each individual siRNA is decreased, while the total amount of
siRNA molecules targeting the same mRNA species main-
tains the same as in the individual screening format.
In the individual siRNA screening format, in theory, dif-
ferent siRNAs targeting the same mRNA species should
induce an identical phenotype. In reality, these siRNAs rarely
lead to the same phenotype because different siRNAs are
heterogeneous in inducing Dicer-mediated degradation of
the target mRNA. Furthermore, a number of phenotypes only
occur while the target is depleted to a certain level. Therefore,
if any two individual siRNAs can conﬁrm the same pheno-
type, they are considered as the ﬁnal hits. Occasionally, a
high proportion of a single siRNA hit may be ignored and
subsequently lead to false negatives in the same assay
(Fig. 2A) (Iorns et al., 2007).
In the pooled shRNA library coupled in next generation
sequencing format, shRNAs are commonly cloned into
speciﬁc vector backbones with unique barcodes. This
approach is widely used for pooled competitive screening, so
it is often called barcode screening and shows improve-
ments in speed and scale compared to array-based
screening. A large population of cells can be infected with a
pool of vector-based shRNAs. After 48–72 h of infection,
cells are then spilt into three or more groups. One group is
immediately frozen as the initial population, the second
group (or additional groups) is treated with speciﬁc selective
pressure(s) for a longer period (14 days or longer), while the
last group is treated with vehicle. After the selective pressure
is applied, cells are harvested from the treatment groups,
and genomic DNAs are extracted from these populations.
Finally integrated shRNAs are recovered using PCR ampli-
ﬁcation followed by next generation sequencing.
If a given shRNA decreases cell viability, the relative
abundance of that shRNA in the vehicle group will decrease
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Figure 2. RNAi high-throughput screening approaches. (A) Arrayed screen using siRNA in a multiwell plate. siRNA can be
reverse-transfected into cells for 48–72 h. Then, cells can be selected using some pressure or left for a longer time period to develop
phenotypes, which can be determined using various readouts. (B) Pooled screen using pooled shRNA viral particles to infect target
cells. After 48 h, cells can be divided into multiple groups. One group can be frozen as an initial population. Other groups can be
treated with various pressures for some period. Then, relative enrichment of shRNAs can be analyzed using next generation
sequencing.
REVIEW Shan Gao et al.
808 © The Author(s) 2014. This article is published with open access at Springerlink.com and journal.hep.com.cn
P
ro
te
in
&
C
e
ll
when compared to the initial population. Similarly, the
shRNA target gene under pressure will affect cell viability, so
its relative abundance in the pressure group will corre-
spondingly decrease when compared to the vehicle group,
which is helpful to indicate the function or network connec-
tion of the target gene (Fig. 2B) (Sims et al., 2011; Corcoran
et al., 2013). Alternatively, pooled shRNA can be used to
infect different cell lines. After the selection period, PCR and
next generation sequencing are employed to determine
which shRNA reagents are under- or over-represented in
these cell lines to deﬁne targets (Silva et al., 2008).
THE APPLICATION OF RNAi HTS TO CANCER
BIOLOGY
The RNAi HTS approach is still at an early stage compared to
many classical genetic screens, but it has already been used
in a large number of studies that show some signiﬁcant
impact in a wide variety of ﬁelds, especially in cancer biology.
Cancer cells acquire a set of mutated genes during carcino-
genesis, and a vast amount of information about these
mutated genes has been accumulated from whole exome
sequencing and next generation sequencing (Berger et al.,
2011; Banerji et al., 2012; Barbieri et al., 2012). However, that
does not mean that all of these mutated genes prompt cancer
development, rather than only a limited mutated genes
causing the cancer (Ashworth et al., 2011). It is crucial to
distinguish which mutated genes are a key driver for survival
and proliferation of cancer cells. Moreover, developing potent
and speciﬁc inhibitors targeting these key mutated genes
represents a hot ﬁeld in targeted cancer therapy, which has
become an important part of many cancer treatment methods
due to its precision in killing cancer cells with relatively few
side effects as compared to traditional chemotherapies.
However, precision often also means narrowness, which is
an intrinsic drawback of targeted cancer therapy. Thus, these
inhibitors often display less effective and limited activity in
killing cancer cells and also allow cancer cells to develop
drug resistance, one of the primary reasons for treatment
failure (Guo and Wang, 2012). The major challenge and key
step for cancer therapy is to identify the target that is essential
for the survival and proliferation of the cancer cells, as well as
biomarkers that are able to predict what types of cancers are
sensitive or resistant to speciﬁc inhibitors. Therefore, RNAi
HTS will be helpful in target selection and selective cancer
patient treatment. Moreover, phenotypic assays to detect cell
number and viability are well established. Thus, it is not
surprising that RNAi HTS was applied to uncover mutant
gene function or therapeutic target identiﬁcation in neoplastic
phenotypes in the earliest studies.
A genome-wide siRNA lethality screen has been per-
formed to identify functional dependencies in two breast cell
lines that were transformed using the same oncogene with
different phenotypes. Proteasome genes were enriched
among the 154 identiﬁed genes that show higher
dependency in basal-like transformed cells than in myoepi-
thelial-like transformed cells. Indeed, basal-like triple nega-
tive breast cancer (TNBC) lines are selectively sensitive to
proteasome inhibitors compared to normal epithelial, lumi-
nal, and mesenchymal TNBC lines (Petrocca et al., 2013).
A genome-wide shRNA library in a pooled format has
been applied to identify genes that regulate sensitivity to RAS
mutant cancer cells in colorectal DLD-1 cells with and without
a mutant form of the oncogene KRAS. A set of mitotic regu-
lators, including ubiquitination, proteasome degradation of
mitotic factors, and PLK1, increase the dependency of
KRAS-mutant cells on mitotic checkpoints and progression.
These KRAS-mutant cell lines are also more sensitive to
treatment with a PLK1 inhibitor in both in vivo and xenograft
models. PLK1 inhibitors (http://www.clinicaltrials.gov/ct2/
results?term=PLK1&Search=Search) and siRNAs (http://
www.tekmira.com/pipeline/tkm-plk1.php) are currently in
clinical trials, and it will be very interesting to determine if RAS
tumors display increased sensitivity in a clinical setting (Luo
et al., 2009). MED12 was identiﬁed as a common determi-
nant of drug resistance using 24,000 shRNAs targeting 8000
human genes in a lung cancer line harboring a translocation
between EML4 and the kinase ALK, which is sensitive to ALK
inhibitors PF-02341066 (crizotinib) and NVP-TAE684. Fur-
thermore MED12 silencing causes resistance to various
tyrosine receptor inhibitors by negatively regulating TGF-βR2
via interaction with TGF-βR2 (Huang et al., 2012).
Although several groups have made signiﬁcant progress
in the identiﬁcation of key oncogenic events and cancer
therapeutic targets using RNAi HTS, nearly all of these
screens were conducted in vitro. Such in vitro screens result
in some key and novel ﬁndings in the studies of cancer cells
but are less able to recapitulate the complex interactions
between tumors and their microenvironment, which is an
important step toward understanding cancer cell growth in a
more physiologic context, as it is not possible to design more
rational treatments for cancers based on in vitro screens
(Mbeunkui and Johann, 2009). Beronja and colleagues
performed an in vivo genome-wide pooled lentiviral shRNA
screen in normal embryonic epidermal tissue and a hyper-
proliferation of HrasG12V-induced neoplasm in mice. A
number of expected and unexpected genes that regulate
embryonic epidermal growth were identiﬁed by the analysis
of relative shRNA abundance. After eliminating genes that
are essential under both conditions and regarded as
housekeeping/viability genes, there are still ∼250 candidates
left that were deﬁned as oncogene-speciﬁc growth regula-
tors. They represent genes that could be targeted in cancer
without causing any ill effect on normal tissue. Among the
top HrasG12V-dependent screen hits were the Wnt effector β-
catenin and myeloid/lymphoid or mixed-lineage leukemia
translocated to 6 (Mllt6). Silencing of either gene in
HrasG12V-expressing epidermal cells diminishes the forma-
tion of HrasG12V-dependent squamous papillomas in mice
and inhibits both the initiation and maintenance of human
RNAi HTS in cancer biology and virology REVIEW
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squamous cell carcinoma xenografts. These results dem-
onstrate the feasibility of this in vivo screening approach and
identify key regulators of oncogenic growth that may repre-
sent potential therapeutic targets (Beronja et al., 2013).
THE APPLICATION OF RNAi HTS IN VIROLOGY
Despite great effort in the antiviral drug development and
vaccination research ﬁelds, viruses are still major threats to
public health. Indeed, despite the availability of several dif-
ferent vaccines, inﬂuenza viruses infect up to one billion
people globally, accounting for ﬁve million cases of severe
disease and 250,000 to 500,000 deaths each year (Girard
et al., 2005; Lambert and Fauci, 2010). In contrast, without a
vaccine after 25 years of research, HIV has infected more
than 70 million people to date and is responsible for 35
million deaths (WHO). Similarly, hepatitis C virus (HCV)
infects 130–170 million people each year, causing acute and
chronic infection (Madan et al., 2014). Dengue virus infects
near 100 million people each year, resulting in half a million
cases of hemorrhagic fever (Hussain and Asgari, 2014). In
addition, viruses are also the major driving forces for certain
types of tumors in humans. High risk types of human papil-
lomaviruses (HPVs) are the causative agent of nearly all
cervical cancers, which is one of the leading causes of
mortality in women (Rositch et al., 2014). Similarly, Epstein-
Barr virus (EBV), which infects 90% of adults worldwide,
plays a key role in certain tumors, including Burkitt’s lym-
phoma, Hodgkin’s disease, and nasopharyngeal carcinomas
(Pattle and Farrell, 2006).
Themost effective way to prevent virus-related diseases is
vaccines. However, in most cases, vaccines are not available
or not always effective. Each year, the protection efﬁcacy of
trivalent inactivated inﬂuenza vaccines (TIVs) is only ∼59% in
the US adult population aged 18–65 years (Osterholm et al.,
2012). Antiviral drugs are therefore critical in controlling viru-
ses. The drugs currently in use mainly target virus proteins or
genomes. However, it is very easy for viruses, especially RNA
viruses, to develop resistance against such drugs due to the
highmutation rates of the viral genomes. To that end, ﬁnding a
more effective way to develop novel drugs has become a
crucial research topic. It has been shown that pooled siRNAs
targeting theZaireEbola virus (ZEBOV) keyproteins including
RNA polymerase L proteins, viral protein (VP) 24 and VP35
efﬁciently protect against ZEBOV in non-human primates,
suggesting thiswill be useful treatment for other emerging viral
infections in human (Geisbert et al., 2010).
Viruses rely on host cells to propagate. Therefore, under-
standing the involvement of host factors in virus infection may
facilitate the discovery of potential drug candidates because
host factors undergomuch lessmutagenic pressure than viral
proteins and may have a universal function during different
virus infections.With the development ofHTSRNAi screens, it
became possible to examine genome-wide interactions
between viruses and host factors.
The Drosophila C virus (DCV), a picornavirus, was the ﬁrst
virus to undergo genome-wide RNAi screening to identify
novel host factors required for internal ribosome entry site
(IRES)-dependent viral translation (Cherry et al., 2005). The
ﬁrst virus in a mammalian system that was screened by
genome wide RNAi is HCV in 2007. In an effort to discover
novel druggable targets against HCV, a library of siRNAs
targeting 4,000 human genes was used to identify genes that
regulate HCV replication in Huh7-derived EN5-3 cells har-
boring an HCV subgenomic replicon (Fig. 3). Nine cellular
genes, including members of the tumor necrosis factor/lym-
photoxin signaling pathway, were identiﬁed (Table 1).
Silencing these genes leads to inhibition of HCV replication,
and the level of siRNA silencing of these host genes corre-
lates well with the inhibition of HCV (Ng et al., 2007).
In 2008, three groups simultaneously reported genome-
wide RNAi HTS for host factors required for HIV replication.
Brass et al. developed a two-part siRNA screen to detect
host factors involved in HIV infection (Brass et al., 2008).
With 21,121 pools of siRNA, they identiﬁed 273 HIV-
dependency factors in TZM-bl cells. Other than 36 host
factors, including CD4, CXCR4, and components of NF-κB
that were previously implicated in HIV pathogenesis, they
revealed the involvement of the Golgi transport proteins
Rab6 and Vps53 in HIV entry, TNPO3 in integration, and
Med28 in transcription. Another group using a siRNA library
composed of 22,329 pools of siRNA targeting 19,709 genes
in HeLa P4/R5 cells detected 311 host factors, with an
18-gene overlap with Brass et al. (Zhou et al., 2008). They
conﬁrmed the involvement of the SP1/mediator complex and
the NF-κB signaling pathway in HIV replication. Meanwhile,
a study focusing on the early steps of HIV-1 infection
revealed >200 genes in human 293T cells that may facilitate
HIV infection. Among them, >40 genes speciﬁcally regulate
the initiation of virus replication (Konig et al., 2008). Although
each screen has an overlapping rate of approximately 6%,
only three host factors were identiﬁed in all three screens,
MED6, MED7 (mediator complex), and RelA (NF-κB com-
plex) (Friedel and Haas, 2011).
Due to the continuous outbreak of seasonal ﬂu and the
2009 pandemic ﬂu, inﬂuenza viruses have been vigorously
studies using genome-wide RNAi screens. An initial attempt
was performed in 2008, covering 90% of the Drosophila
genome (Hao et al., 2008). Based on a Renilla luciferase
reporter gene, >100 host factors were identiﬁed that alter
inﬂuenza replication, including the cytochrome c oxidase
subunit COX6A1, the ATPase ATP6VoD1, and the nuclear
export factor NXF1/TAP. The interferon-inducible trans-
membrane proteins IFITM1, 2, and 3 were later discovered to
restrict the early stage of inﬂuenza A virus replication via a
siRNA screen in osteosarcoma cells (U2OS) (Brass et al.,
2009). Further tests targeting 19,000 human genes were
performed in human lung epithelial A549 cells in 2010 (Konig
et al., 2010). Among the 295 host factors identiﬁed, 23 factors
are necessary for inﬂuenza virus entry, and 10 factors are
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required for post-entry steps.Konig et al. conﬁrmseveral of the
factors using small molecule inhibitors, including that the
vATPase and CAMK2B are indeed essential for inﬂuenza
replication. In addition, a HTS RNAi study using pandemic
swine-origin inﬂuenza virus identiﬁed 168 factors that inhibit
virus infection, including the SON DNA binding protein (SON)
that controls the trafﬁcking of virions to late endosomes, as
well as CDC-like kinase 1 (CLK1). In depth assays further
uncovered the role of cyclin-dependent kinase inhibitor 1B
(Cdkn1b) in inﬂuenza infection by using p27-/- mice (Karlas
et al., 2010).
Careful design of RNAi screens also revealed detailed
and speciﬁc information for poxvirus infection. A library was
used to screen 7,000 druggable genes in HeLa cells and
   
siRNA library transfection
24–96 h
24–96 h
Infect with virus
Luciferase reporter assay
Konig et al., 2008
Karlas  et al., 2010
Konig et al., 2010
Tat-dependent reporter assay
Brass et al., 2008
Zhou et al., 2008
p24 detection
Brass et al., 2008
GFP detection
Mercer et al., 2012
Sivan et al., 2013
Hit analysis (semifinalists)
Additional screen with 
individual siRNAs
Results
(or further tests with drugs)
Figure 3. Work ﬂow of genome wide siRNA screen for viral related host factor. Cells are initially transfected with different siRNA
libraries, and then infected with viruses. Different assays can be utilized to detect screen results, including luciferase reporter assay,
Tat-dependent reporter assay, p24 detection, as well as GFP detection. After ﬁrst round of screen, hit analysis is performed and the
candidates are subject to additional screen with individual siRNAs.
Table 1. Genome-wide siRNA screen for host factors related to virus infections
Virus Group Cells Gene targeted siRNAs
per gene
Host factors identiﬁed
HCV Ng et al. (2007) EN5-3 (Huh7) 4000 4 9
HIV Brass et al. (2008) TZM-bl 21,121 4 273 3 overlap
MED6, MED7, RelA.
Zhou et al. (2008) P4/R5 (HeLa) 19,709 3 311
Konig et al. (2008) HEK-293T 19,628 6 295
Inﬂuenza Hao et al. (2008) DL1 13,071 4 100 3 overlap
ARCN1, ATP6AP1, COPG
Brass et al. (2009) U2OS 17,877 4 250
Konig et al. (2010) A549 19,000 4 295
Karlas et al. (2010) A549 22,843 4 168
VACV Mercer et al. (2012) HeLa MZ 6979 3 188 23 overlap
Sivan et al. (2013) HeLa 21,566 4 500
RNAi HTS in cancer biology and virology REVIEW
© The Author(s) 2014. This article is published with open access at Springerlink.com and journal.hep.com.cn 811
P
ro
te
in
&
C
e
ll
clearly shows that Cullin3-based ubiquitination is needed to
initiate vaccinia virus (VACV) DNA replication (Mercer et al.,
2012). In another study, >500 genes that signiﬁcantly inhibit,
and a similar number that enhance, the replication and
spread of VACV were identiﬁed from RNAi HTSs with two
independent human genome-scale libraries. Functional
studies demonstrate that silencing nucleoporin 62 strongly
inhibits VACV morphogenesis and has only a modest effect
on viral gene expression, thus recapitulating and providing
insight into previous studies with enucleated cells (Sivan
et al., 2013).
CONCLUSIONS AND FUTURE PERSPECTIVE
As demonstrated by the various studies described above, the
applications of RNAi HTS have been successful for the
identiﬁcation of novel genes that regulated cancer cell growth
(either in vivo or in vitro) and mediated the interactions
between viruses and hosts. RNAi HTS has a more broad
application as a powerful tool to identify gene networks in a
given biological process. Although this approach has been
successfully applied in many studies, challenges remain in
understanding screen results and, particularly, determining
the signiﬁcance in clinical applications. For example, many
studies related to KRAS-driven oncogenic events reveal dif-
ferent major determinants in different cancer cell lines. The
non-canonical IκB kinase TBK1 was ﬁrst identiﬁed as a major
regulator of mutated KRAS in various cancer cell lines (Bar-
bie et al., 2009). Subsequently, TAK1 and TATA2 have also
been found to regulate mutated KRAS in colon cancer cell
lines and non-small cell lung cancer cell lines, respectively
(Kumar et al., 2012; Singh et al., 2012). However, a set of
mitotic regulators including PLK1 is more important in an
isogenic colon cancer cell line (Luo et al., 2009) (Table 2).
There are no major overlapping regulators in these studies.
This may be caused by investigators using different cell lines
with various genetic backgrounds, but these discrepancies
may also be caused by unknown reasons.
In another example, for the identiﬁcation of host regula-
tors for HIV replication mentioned as above, overlaps were
very limited among the three studies described (Table 1).
The largest overlaps were observed between the studies of
(Brass et al., 2008) and (Zhou et al., 2008). They use HeLa
and HeLa-derived TZM-bl cells and focus on the entire virus
life cycle as an interesting biological question. By contrast,
König et al. analyzed only the processes subsequent to HIV-1
entry, used different cell lines (293T) (Konig et al., 2008), and
show less overlapping results with the other two studies.
Collectively, this leaves one big question: how can one
interpret the results from different RNAi HTS experiments? The
reasons for the large discrepancies are most likely differences
in the experimental setups, such as the cell culture systems,
different assays for phenotype detecting, and the various RNAi
librariesused in thesestudies. Itwill becrucial tocarefully deﬁne
standards for RNAi HTS. The standards will ensure and guide
different research groups to generate RNAi HTS datasets as
common annotation guidelines for disseminating data online.
This will be helpful to compare the datasets generated by dif-
ferent groups and facilitate information sharing.
Also it is difﬁcult, if ever possible to mimic many physio-
logical phenotypes and micro-environments in the cell-based
assays. Therefore, in vivo RNAi HTS assays as described in
mice (Beronja et al., 2013; Fellmann and Lowe, 2014) are
likely to become an essential technology advance that facil-
itates gene function identiﬁcations in physiological context.
For example, in cancer biology, given the complex interac-
tions of a tumor and its microenvironment, including the
communications between tumor cells and surrounding cells
(Hanahan andWeinberg, 2011), cell-based in vitro RNAi HTS
may not able to discover the ideal therapeutic target. How-
ever, in vivo HTS will provide comprehensive information in
much more physiologically relevant conditions, thus should
support better design and execution for cancer therapy.
The combination of RNAi HTS and other genomic, tran-
scriptomic, proteomic, andmicemodeling techniqueswill lead
to asystemic understandingof genenetworks,whicharemore
relevant in a physiological context. In the future, we anticipate
that RNAi HTS will be applied as the very ﬁrst step of many
researchendeavors, and the results of the screenswill provide
lead information to design deﬁned validation experiments.
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ABBREVIATIONS
EBV, Epstein-Barr virus; dsRNA, double-stranded RNA; HCV,
hepatitis C virus; HPV, human papillomaviruses; HTS, high-
Table 2. RNAi high-throughout screening for genes sensitive to mutated KRAS
Group Cells Libraries Characterized genes
Barbie et al. (2009) 19 cell lines with wild-type or mutated RAS Kinase, phosphatase and oncogenes TBK1
Luo et al. (2009) Isogenic DLD-1 Genome-wide PLK1
Kumar et al. (2012) 28 NSCLC cell lines 7000 human genes GATA2
Singh et al. (2012) 21 mutated KRAS colon cancer cell lines Kinase TAK1
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throughput screening; RISC, RNA-induced silencing complex; RNAi,
RNA interference; shRNA, short hairpin RNA; siRNA, short
interfering RNA; TNBC, basal-like triple negative breast cancer.
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